This is a working overview of Research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-31 and is reviewed periodically as new material appears.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
== History == High-level vancomycin-resistant E. faecalis and E. faecium are clinical isolates first documented in Europe in 1986 and the United States in 1987. In the United States, vancomycin-resistant E. faecium was associated with 4% of healthcare-associated infections reported to the Centers for Disease Control and Prevention National Healthcare Safety Network from January 2006 to October 2007. VRE can be carried by healthy people who have come into contact with the bacteria, usually in a hospital (nosocomial infection), although it is thought that a significant percentage of intensively farmed chickens also carry VRE. Other regions have noted a similar distribution, but with increased incidence of VRE. For example, a 2006 study of nosocomial VRE revealed a rapid spread of resistance among enterococci along with an emerging shift in VRE distribution in the Middle East region, such as Iran. Treatment failures in enterococcal infections result from inadequate information regarding the glycopeptide resistance of endemic enterococci due to factors such as the presence of VanA and VanB. The study from Iran reported the first case of VRE isolates that carried the VanB gene in enterococcal strains from Iran. This study also noted the first documented isolation of nosocomial Enterococcus raffinosus and Enterococcus mundtii in the Middle East region.
The Gβγ sub-unit binds to the intracellular loop between the two trans-membrane helices of the VDCC. When the sub-unit binds to the voltage-dependent calcium channel, it produces a voltage-dependent block, which inhibits the channel, preventing the flow of calcium ions into the neuron. Embedded in the cell membrane is also the G protein-coupled inwardly-rectifying potassium channel. When a Gβγ or Gα(GTP) molecule binds to the C-terminus of the potassium channel, it becomes active, and potassium ions are pumped out of the neuron. The activation of the potassium channel and subsequent deactivation of the calcium channel causes membrane hyperpolarization. This is when there is a change in the membrane's potential, so that it becomes more negative. The reduction in calcium ions causes a reduction of neurotransmitter release because calcium is essential for this event to occur. This means that neurotransmitters such as glutamate and substance P cannot be released from the presynaptic terminal of the neurons. Substance P is a believed to help sensitize postsynaptic neurons to glutamate, aiding in the transmission of pain signals from periphery nerves to the brain. These neurotransmitters are vital in the transmission of pain, and as β-Endorphin reduces the release of these substances, there is a strong analgesic effect.
=== GCCA === The Global Cold Chain Alliance officially launched in April 2007. The Alliance now acts as the platform for communication, networking and education for each link of the cold chain. It serves as the voice of the cold chain industry. The International Association of Refrigerated Warehouses (IARW) and the World Food Logistics Organization (WFLO) had a history of serving the food industry through the twentieth century and the impressive development of refrigeration in the movement of food products. In the 21st century, many IARW and WFLO members realized changes in their business models were necessary as global conditions required greater integration of the cold chain. This reform of integration created closer relationships among all players in the supply chain, which lead to developments such as dedicated distribution facilities and public refrigerated warehouse (PRW) trucking assets. The WFLO became a core partner of the alliance.
=== Ships === Ships in the Culture are intelligent individuals, often of very large size, controlled by one or more Minds. The ship is considered by the Culture generally and the Mind itself to be the Mind's body (compare avatars). Some ships (GSVs, for example) are tens or even hundreds of kilometres in length and may have millions or even billions of residents who live on them full-time; together with Orbitals, such ships represent the main form of habitat for the Culture. Such large ships may temporarily contain smaller ships with their own populations, and/or manufacture such ships themselves. In Use of Weapons, the protagonist Zakalwe is allowed to acclimatise himself to the Culture by wandering for days through the habitable levels of a ship (the GSV Size Isn't Everything, which is described as over 80 kilometres (50 mi) long), eating and sleeping at the many locations which provide food and accommodation throughout the structure and enjoying the various forms of contact possible with the friendly and accommodating inhabitants.
=== Arthroplasty of the knee with artificial implant === Total Knee Arthroplasty was first re-designed in England and developed in the USA during the early seventies of the previous Century. In 1975 first time in Israel, Knee Arthroplasty was done in the Center for Implant Surgery in Haifa. Within short time the procedure was routinely done in other Israeli Orthopedic departments, years ahead prior to its penetration into European Orthopedics
Sources: en.wikipedia.org
=== Minerals === At the bottom of the chain, minerals were unable to move, sense, grow, or reproduce. Their attributes were being solid and strong, while the gemstones possessed magic. The king of gems was the diamond.
Donald Trump began his second term with another historically low job approval rating, only improving on his lowest-ever rating (occurring in his first term) by three percentage points. President Trump began his first term at 45% job approval, and his second with 47%. According to Gallup, "Trump remains the only elected president with sub-50% initial approval ratings". In a CBS News/YouGov poll conducted from February 5–7, 2025, Trump reached a career high poll rating of 53%. According to ABC News, Trump's approval rating at the end of his first 100 days in office was 39%, even lower than his already low 42% approval rating at the end of his first 100 days of his first presidency and the worst of any president's approval ratings after their 100 days in 80 years. By July 2025, Gallup found Trump's approval rating reached the lowest for his second term at 37%, largely driven by declining support from independents, and in August, multiple surveys revealed record or near-record low job approval ratings, which Gallup found to be lower than any modern president. As was the case during Trump's first term, the president's approval ratings have remained remarkably stable. His ratings are also very polarized, often with more Republicans than Democrats approving of his leadership. In May 2026, a Washington Post–ABC News–Ipsos poll reported declining approval of Trump's leadership, with respondents expressing dissatisfaction over issues including the Iran war and economic policy.
Microorganisms may also be identified using automated systems, such as instruments that perform panels of biochemical tests, or matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), in which microbial proteins are ionized and characterized on the basis of their mass-to-charge ratios; each microbial species exhibits a characteristic pattern of proteins when analyzed through mass spectrometry. Because bloodstream infections can be life-threatening, timely diagnosis and treatment is critical, and to this end several rapid identification methods have been developed. MALDI-TOF can be used to identify organisms directly from positive blood culture bottles after separation and concentration procedures, or from preliminary growth on the agar plate within a few hours of subculturing. Genetic methods such as polymerase chain reaction (PCR) and microarrays can identify microorganisms by detection of DNA sequences specific to certain species in blood culture samples. Several systems designed for the identification of common blood culture pathogens are commercially available. Some biochemical and immunologic tests can be performed directly on positive blood cultures, such as the tube coagulase test for identification of S. aureus or latex agglutination tests for Streptococcus pneumoniae, and unlike PCR and MALDI-TOF, these methods may be practical for laboratories in low and middle income countries.
=== Parkinson's disease === Barran has been working with Joy Milne to search for odorous biomarkers of Parkinson's disease. By smelling skin swabs, Milne says she can differentiate between people with and without Parkinson's disease. She says she identified changes in her husband's scent before he was formally diagnosed with Parkinson's disease, which he died of in 2015. Barran uses mass spectrometry to investigate the biomarkers of Parkinson's disease. The story was made into a BBC documentary The Woman Who Can Smell Parkinson's. Barran received ethical approval for her work of the skin metabolites of Parkinson's in 2015, allowing them to work with Parkinson's UK to conduct a larger study. In 2018 Milne travelled to the Tanzanian training centre APOPO to check whether she could smell Tuberculosis. Barran's work on Parkinson's is sponsored by The Michael J. Fox Foundation. In 2022, Barran and others published a study of a method to detect Parkinson's disease by analysing sebum using mass spectrometry.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.